Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Coronavirus COVID-19 In Vitro Diagnostics Artificial Intelligence

Renalytix AI Launches Trial To Identify COVID-19 Patients With Kidney Injury

  • News

Executive Summary

The Mount Sinai spin-off believes its KindeyIntelX system can identify COVID-19 patients at high risk for long-term kidney damage.

You may also be interested in...



JPM 2021: Intuitive Surgical, Accelerate Diagnostics, Siemens Healthineers, Exact Sciences, Renalytix

The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the third day of the meeting.

Kantaro Sees Important Role For New Antibody Test During Next Phase Of Pandemic

The company is planning to produce up to 10 million COVID-SeroKlir SARS-CoV-2 IgG antibody test kits a month through a partnership with Bio-Techne.

IPOs Are Back: Liquid Biopsy, Cardio, Dialysis Firms Lead $1.5Bn Charge

Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Coronavirus COVID-19 In Vitro Diagnostics Artificial Intelligence
UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By